Instrument Inactif

Communiqués Zeltia SA

Actions

ES0184940817

Recherche biotechnologique et médicale

Cours en clôture BME
- ^EUR	-

14/12/15	DJ Industrial : Wall Street termine dans le vert une séance volatile	RE
17/11/15	China CITIC Bank : Les valeurs à suivre sur les marchés américains	RE

Communiqués

26/10/15	Zeltia : PharmaMar to Present New Studies for YONDELIS® and PM1183 in Ovarian Cancer during ESGO 2015	PU
23/10/15	Zeltia : U.S. FDA Approves YONDELIS® (trabectedin) for Soft Tissue Sarcoma (Liposarcoma or Leiomyosarcoma)	PU
21/10/15	Zeltia : Grupo Zeltia reports 126.8 million euro in net sales (+8.5%) in the first nine months of 2015	PU
21/09/15	Zeltia : Enrollment of first patient in a Phase II trabectedin study in brain tumor type called meningioma	PU
17/09/15	Zeltia : PharmaMar initiates a phase II “Basket” trial for PM1183 in selected advanced solid tumors	PU
15/09/15	Zeltia : PharmaMar opens new affiliate in UK	PU
01/09/15	Zeltia : Pharmaceutical Council Recommends Approval of YONDELIS® (trabectedin) in Japan	PU
20/08/15	Zeltia : PharmaMar announces license agreement with Specialised Therapeutics Australia Pty for APLIDIN® (plitidepsin) in oncology	PU
31/07/15	Zeltia : PharmaMar passes the U.S. FDA manufacturing inspection for YONDELIS® active ingredient	PU
28/07/15	Zeltia : Grupo Zeltia Reports First Half 2015 Financial Results	PU
23/07/15	Zeltia : PharmaMar announces license agreement with TTY Biopharm for APLIDIN® (plitidepsin) in hematological cancers	PU
22/07/15	Zeltia : GENOMICA and the Foundation for Excellence and Quality in Oncology announce a framework agreement for collaboration in Oncology	PU
29/06/15	Zeltia : PharmaMar initiates the phase III study CORAIL for the anticancer agent PM1183 in patients with platinum-resistant ovarian cancer	PU
02/06/15	Zeltia : PharmaMar announces that Janssen´s study shows that trabectedin improves disease control in patients with advanced soft tissue sarcoma	PU
01/06/15	Zeltia : PharmaMar completes patient recruitment of Phase III registration trial (ADMYRE) with APLIDIN® (plitidepsin) in multiple myeloma	PU
01/06/15	Zeltia : PharmaMar finaliza el reclutamiento de pacientes del ensayo de Fase III de registro (ADMYRE) con APLIDIN® (plitidepsin) en mieloma múltiple	PU
27/04/15	Zeltia : Grupo Zeltia Reports First Quarter 2015 Financial Results	PU
14/04/15	Zeltia : PharmaMar to present data on anticancer candidates PM1183 and plitidepsin at the AACR Annual Meeting 2015	PU
13/03/15	Zeltia : joins World Rare Disease Day	PU
13/03/15	Zeltia : Grupo Zeltia net attributable profit amounted to 13 million euro in 2014 (+16%)	PU
13/03/15	Zeltia : Board of Directors will propose to the next Shareholders' Meeting that Pharma Mar merge with and absorb its parent company, Zeltia	PU
13/01/15	Zeltia : PharmaMar will start a Phase III study of PM1183 in combination with doxorubicin in relapsed SCLC	PU
05/01/15	Zeltia : PharmaMar announces that Taiho Pharmaceutical has submitted a New Drug Application (J-NDA) for Yondelis® (trabectedin) to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for different subtypes of soft tissue sarcoma	PU
04/12/14	Zeltia : PharmaMar reports Phase IIb results for PM1183 showing a median overall survival of 18.1 months compared to 8.5 months for topotecan in platinum-resistant ovarian cancer patients	PU
02/12/14	Zeltia : announces that its Board of Directors has approved a strategy to explore merging PharmaMar and Zeltia in advance of a listing request in the US	PU